Organization

Hoth Therapeutics

1 clinical trial

Clinical trial

A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Status: Recruiting, Estimated PCD: 2024-12-30